PortalPublikationenThe current consensus on the clinical management of intracra...

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

Standard

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. / Pajtler, Kristian W; Mack, Stephen C; Ramaswamy, Vijay; Smith, Christian A; Witt, Hendrik; Smith, Amy; Hansford, Jordan R; von Hoff, Katja; Wright, Karen D; Hwang, Eugene; Frappaz, Didier; Kanemura, Yonehiro; Massimino, Maura; Faure-Conter, Cécile; Modena, Piergiorgio; Tabori, Uri; Warren, Katherine E; Holland, Eric C; Ichimura, Koichi; Giangaspero, Felice; Castel, David; von Deimling, Andreas; Kool, Marcel; Dirks, Peter B; Grundy, Richard G; Foreman, Nicholas K; Gajjar, Amar; Korshunov, Andrey; Finlay, Jonathan; Gilbertson, Richard J; Ellison, David W; Aldape, Kenneth D; Merchant, Thomas E; Bouffet, Eric; Pfister, Stefan M; Taylor, Michael D.

in: ACTA NEUROPATHOL, Jahrgang 133, Nr. 1, 01.2017, S. 5-12.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pajtler, KW, Mack, SC, Ramaswamy, V, Smith, CA, Witt, H, Smith, A, Hansford, JR, von Hoff, K, Wright, KD, Hwang, E, Frappaz, D, Kanemura, Y, Massimino, M, Faure-Conter, C, Modena, P, Tabori, U, Warren, KE, Holland, EC, Ichimura, K, Giangaspero, F, Castel, D, von Deimling, A, Kool, M, Dirks, PB, Grundy, RG, Foreman, NK, Gajjar, A, Korshunov, A, Finlay, J, Gilbertson, RJ, Ellison, DW, Aldape, KD, Merchant, TE, Bouffet, E, Pfister, SM & Taylor, MD 2017, 'The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants', ACTA NEUROPATHOL, Jg. 133, Nr. 1, S. 5-12. https://doi.org/10.1007/s00401-016-1643-0

APA

Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., Hansford, J. R., von Hoff, K., Wright, K. D., Hwang, E., Frappaz, D., Kanemura, Y., Massimino, M., Faure-Conter, C., Modena, P., Tabori, U., Warren, K. E., Holland, E. C., Ichimura, K., ... Taylor, M. D. (2017). The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. ACTA NEUROPATHOL, 133(1), 5-12. https://doi.org/10.1007/s00401-016-1643-0

Vancouver

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. ACTA NEUROPATHOL. 2017 Jan;133(1):5-12. https://doi.org/10.1007/s00401-016-1643-0

Bibtex

@article{e6a7f60326d246de98968b3dd9524776,
title = "The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants",
abstract = "Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.",
author = "Pajtler, {Kristian W} and Mack, {Stephen C} and Vijay Ramaswamy and Smith, {Christian A} and Hendrik Witt and Amy Smith and Hansford, {Jordan R} and {von Hoff}, Katja and Wright, {Karen D} and Eugene Hwang and Didier Frappaz and Yonehiro Kanemura and Maura Massimino and C{\'e}cile Faure-Conter and Piergiorgio Modena and Uri Tabori and Warren, {Katherine E} and Holland, {Eric C} and Koichi Ichimura and Felice Giangaspero and David Castel and {von Deimling}, Andreas and Marcel Kool and Dirks, {Peter B} and Grundy, {Richard G} and Foreman, {Nicholas K} and Amar Gajjar and Andrey Korshunov and Jonathan Finlay and Gilbertson, {Richard J} and Ellison, {David W} and Aldape, {Kenneth D} and Merchant, {Thomas E} and Eric Bouffet and Pfister, {Stefan M} and Taylor, {Michael D}",
year = "2017",
month = jan,
doi = "10.1007/s00401-016-1643-0",
language = "English",
volume = "133",
pages = "5--12",
journal = "ACTA NEUROPATHOL",
issn = "0001-6322",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

AU - Pajtler, Kristian W

AU - Mack, Stephen C

AU - Ramaswamy, Vijay

AU - Smith, Christian A

AU - Witt, Hendrik

AU - Smith, Amy

AU - Hansford, Jordan R

AU - von Hoff, Katja

AU - Wright, Karen D

AU - Hwang, Eugene

AU - Frappaz, Didier

AU - Kanemura, Yonehiro

AU - Massimino, Maura

AU - Faure-Conter, Cécile

AU - Modena, Piergiorgio

AU - Tabori, Uri

AU - Warren, Katherine E

AU - Holland, Eric C

AU - Ichimura, Koichi

AU - Giangaspero, Felice

AU - Castel, David

AU - von Deimling, Andreas

AU - Kool, Marcel

AU - Dirks, Peter B

AU - Grundy, Richard G

AU - Foreman, Nicholas K

AU - Gajjar, Amar

AU - Korshunov, Andrey

AU - Finlay, Jonathan

AU - Gilbertson, Richard J

AU - Ellison, David W

AU - Aldape, Kenneth D

AU - Merchant, Thomas E

AU - Bouffet, Eric

AU - Pfister, Stefan M

AU - Taylor, Michael D

PY - 2017/1

Y1 - 2017/1

N2 - Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

AB - Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

U2 - 10.1007/s00401-016-1643-0

DO - 10.1007/s00401-016-1643-0

M3 - SCORING: Journal article

C2 - 27858204

VL - 133

SP - 5

EP - 12

JO - ACTA NEUROPATHOL

JF - ACTA NEUROPATHOL

SN - 0001-6322

IS - 1

ER -